Carbolin100 ml

Carbolin is a mucolytic (mucoregulator) agent used to reduce the viscosity of thick, tenacious mucus in respiratory conditions where excessive or sticky sputum causes airway obstruction and impairs clearance.

Established/Guideline-supported uses

• Chronic bronchitis and chronic obstructive pulmonary disease (COPD) with productive cough, to aid expectoration and reduce sputum viscosity
• Acute bronchitis with thick sputum
• Bronchiectasis
• Chronic sinusitis and secretory otitis media (glue ear), to aid drainage of thick secretions

Adjunct uses

• As an adjunct in bronchial asthma and pharyngo-laryngitis where excessive thick mucus is a contributing symptom
• As an adjunct to antibiotic therapy in respiratory infections associated with pulmonary tuberculosis, to improve mucus clearance (not as a substitute for anti-tubercular treatment)

Note: Carbolin is not a treatment for the underlying infection or disease process; it works on mucus consistency only and should be used alongside appropriate disease-specific treatment.

Each formulation contains Carbocisteine as the active ingredient, commonly available as capsules (375 mg) and oral syrup (125 mg/5 mL and 250 mg/5 mL). Excipients vary by manufacturer and formulation (e.g., sweeteners, preservatives, flavoring agents in syrups).

Carbolin is a carbocysteine-class mucoactive (mucolytic/mucoregulator) drug that alters the physical and chemical properties of respiratory mucus. It is widely used across Asia and Europe for productive respiratory conditions in which thick, sticky secretions are difficult to clear.

Unlike cough suppressants, Carbolin does not act on the cough reflex; instead, it makes mucus less viscous so that it can be cleared more easily by coughing or ciliary action.

Mucolytic / Expectorant (Mucoactive agent)

Carbocisteine acts on the sialomucin-producing goblet cells of the respiratory mucosa. It reduces the viscosity of respiratory secretions primarily through two mechanisms:

• Breaking disulfide bonds within mucus glycoprotein (mucin) molecules, which reduces cross-linking and lowers the overall viscosity of the mucus gel
• Normalizing the balance of sialomucins and fucomucins secreted by the bronchial mucosa, restoring a more physiological (less viscous, more easily cleared) mucus composition

By making mucus thinner and less sticky, Carbocisteine facilitates its removal by cilia and coughing, helping to relieve airway obstruction caused by thick secretions.

Take by mouth, preferably with or after food, with a full glass of water. Use the measuring cup/spoon provided for syrup formulations. Do not alter the dose without consulting a physician.

Carbolin has a relatively low potential for clinically significant drug interactions, but the following should be noted:

• Cough suppressants (antitussives, e.g., codeine, dextromethorphan): Concurrent use may cause dangerous accumulation of loosened mucus in the airway due to suppression of the cough reflex needed to clear it; concomitant use is generally discouraged.
• Antibiotics (e.g., amoxicillin, doxycycline): Some mucolytics can theoretically alter local drug penetration into respiratory secretions; clinically significant interaction with Carbolin is not well established, but spacing doses is a reasonable precaution if advised by a physician.

Always inform your physician or pharmacist of all medicines, supplements, and herbal products you are taking before starting Carbolin.

Most adverse effects associated with Carbolin are mild and gastrointestinal in nature:

• Nausea, vomiting
• Diarrhea
• Gastrointestinal discomfort/epigastric pain
• Gastrointestinal bleeding (rare, more likely in patients with a history of peptic ulcer disease)
• Skin rash and other hypersensitivity reactions (uncommon)
• Headache (uncommon)

Seek medical attention if severe abdominal pain, black/tarry stools, vomiting blood, or signs of an allergic reaction (rash, swelling, difficulty breathing) occur while taking Carbolin.

Pregnancy: Carbolin is not recommended during the first trimester of pregnancy as a precautionary measure, in line with conventional labeling guidance. For the remainder of pregnancy, Carbolin should be used only if clearly needed and if the potential benefit justifies the potential risk to the fetus; a physician should always be consulted before use in pregnancy.

Lactation: There is limited data on the excretion of Carbolin into breast milk. As a precaution, use during breastfeeding should occur only under medical advice, weighing benefit against unknown risk to the infant.

Use Carbolin with caution in patients with a history of peptic ulcer disease, as it may cause gastric mucosal irritation or erosion by disrupting the protective gastric mucus barrier; monitor for gastrointestinal bleeding symptoms in such patients.

Carbolin should not be used together with cough-suppressing (antitussive) medicines, as this can lead to dangerous retention of loosened mucus in the respiratory tract (see Interactions).

Use with caution in elderly or debilitated patients who have a weak cough reflex, since increased mucus mobilization without effective clearance could theoretically worsen airway obstruction.

Discontinue and seek medical advice if signs of gastrointestinal bleeding or hypersensitivity reactions occur (see Side Effects and Contraindications).

Reported overdose experience with Carbolin is limited; gastrointestinal symptoms such as nausea, vomiting, diarrhea, and abdominal pain may be expected to be more pronounced. There is no specific antidote. In case of suspected overdose, seek immediate medical attention or contact a poison control center; treatment is supportive and symptomatic, and should be managed by qualified medical personnel.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric use: Carbolin may be used in children from 2 years of age at the doses described above, under medical supervision. Use in infants below 2 years is generally not established and not recommended; dosage in this age group has not been established.

Elderly: No specific dose adjustment is generally required, but caution is advised in elderly patients with reduced cough reflex or gastrointestinal fragility (see Precautions).

Renal/Hepatic impairment: There is limited specific data on dose adjustment of Carbolin in renal or hepatic impairment; use with caution and under medical supervision in such patients.

Peptic ulcer history: See Precautions and Warnings.

Duration of treatment with Carbolin depends on the underlying condition and clinical response, and is typically continued for as long as excess, thick mucus production persists, as directed by a physician. Long-term use in chronic conditions (e.g., chronic bronchitis, bronchiectasis) should be periodically reviewed by the prescribing physician.

Mucolytics; Mucoactive/Mucoregulatory agents; Respiratory secretion modifiers

Carbocisteine reduces mucus viscosity by breaking disulfide bonds in mucin glycoproteins and by normalizing the sialomucin/fucomucin balance produced by the bronchial mucosa, resulting in thinner, more easily cleared respiratory secretions.

Carbolin is used in children aged 2 years and above for thick-mucus respiratory conditions, at reduced weight/age-appropriate doses (see Dosage and Administration). Safety and efficacy in infants below 2 years have not been established, and use in this age group is generally not recommended. Pediatric use should always be initiated and monitored by a physician.